Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ipilimumab in Cervical Cancer (COLIBRI)
NCT04256213Phase 2Completed
- Sponsor
- ARCAGY
- Start
- Jul 2020
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in cervical squamous cell carcinoma (CSCC), sponsored by ARCAGY. Primary endpoint: Relative change of CD8+/FOXP3+ ratio of lymphocytes. Started Jul 2020; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on NCT04256213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04256213.